Last reviewed · How we verify
Raltegravir and rifapentine
At a glance
| Generic name | Raltegravir and rifapentine |
|---|---|
| Also known as | Isentress - Raltegravir, Priftin - Rifapentine |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: